Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
by ecancer reporter Vanessa Lane
Cereblon (CRBN) is a primary teratogenic target for thalidomide in the anti-myeloma activity of immunomodulatory drugs (IMiDs).
In in vitro and in vivo studies, the majority of myeloma cell lines and patients resistant to IMiDs show very low levels of CRBN.
Interestingly, although CRBN depletion is initially cytotoxic to human myeloma cells, surviving myeloma cells with stable CRBN depletion have been found to become highly resistant to both lenalidomide and pomalidomide.
However, this is not seen with the unrelated drugs bortezomib, dexamethasone and melphalan.
This studies suggest that expression of CBRN may help to predict response to IMiD therapy and survival outcomes. However, future studies are needed to confirm this.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.